JACC Podcast â Details, episodes & analysis
Podcast details
Technical and general information from the podcast's RSS feed.

JACC Podcast
American College of Cardiology
Frequency: 1 episode/1d. Total Eps: 766

Recent rankings
Latest chart positions across Apple Podcasts and Spotify rankings.
Apple Podcasts
đēđ¸ USA - medicine
05/08/2025#97đĢđˇ France - medicine
05/08/2025#82đ¨đĻ Canada - medicine
04/08/2025#66đĢđˇ France - medicine
04/08/2025#62đēđ¸ USA - medicine
03/08/2025#96đĢđˇ France - medicine
03/08/2025#36đ¨đĻ Canada - medicine
02/08/2025#77đ¨đĻ Canada - medicine
01/08/2025#73đ¨đĻ Canada - medicine
29/07/2025#68đēđ¸ USA - medicine
29/07/2025#98
Spotify
No recent rankings available
Shared links between episodes and podcasts
Links found in episode descriptions and other podcasts that share them.
See allRSS feed quality and score
Technical evaluation of the podcast's RSS feed quality and structure.
See allScore global : 38%
Publication history
Monthly episode publishing history over the past years.
Serial Shock Severity Assessment: Some Answers. Still Many Questions. | ESC 2024
samedi 31 aoÃģt 2024 âĸ Duration 11:36
Rasha K. Al-Lamee, MD, PhD, JACC Deputy Editor and Navin K. Kapur MD discuss the work from the Cardiogenic Shock Working Group, which is an academic research consortium comprising ~40 hospitals in the U.S. and internationally.
Insights from RESHAPE-HF2 Trial | ESC 2024
samedi 31 aoÃģt 2024 âĸ Duration 13:30
Aakriti Gupta, MD, FACC, JACC Executive Associate Editor, and Stefan D. Anker, MD, discuss the insights from the RESHAPE-HF2 trial - an eight-year study on the efficacy of transcatheter edge-to-edge repair for mitral valve regurgitation in patients with heart failure.
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM
lundi 26 aoÃģt 2024 âĸ Duration 11:19
In the September 3, 2024, JACC issue, a major study evaluates the cardiovascular outcomes of second-line antihyperglycemic agents in type 2 diabetes, comparing SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The research reveals that SGLT2 inhibitors and GLP-1 receptor agonists offer superior cardiovascular protection over the other agents, highlighting their importance for patients with cardiovascular conditions.
JACC - May 28, 2024 Issue Summary
lundi 20 mai 2024 âĸ Duration 25:46
Audio Summary of the May 28 issue of JACC, by Dr. Valentin Fuster
Safety and Efficacy of Metabolic Modulation with Ninerafaxstat in Nonobstructive Hypertrophic Cardiomyopathy: Phase 2 Study
lundi 20 mai 2024 âĸ Duration 13:02
Commentary by Dr. Valentin Fuster
Clinical Outcome of Different Microvascular Injury Patterns after STEMI - A Multicenter Cardiac MRI Study
lundi 20 mai 2024 âĸ Duration 13:41
Commentary by Dr. Valentin Fuster
Prognostic Value of MRR After Primary PCI: a Pooled Analysis of Individual Patient Data
lundi 20 mai 2024 âĸ Duration 10:49
Commentary by Dr. Valentin Fuster
A Technology-Assisted Web Application for Consumer Access to a Non-prescription Statin Medication
lundi 20 mai 2024 âĸ Duration 08:18
Commentary by Dr. Valentin Fuster
Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review
lundi 20 mai 2024 âĸ Duration 21:51
Commentary by Dr. Valentin Fuster
Clinical Risk Assessment Across the Lifespan in Patients with Congenital Heart Disease: JACC Scientific Statement
lundi 20 mai 2024 âĸ Duration 06:42
Commentary by Dr. Valentin Fuster